ClinicalTrials.gg
CompletedNCT03337880Updated Jan 29, 2019

Neonatal Outcomes in Instrumental Delivery

An observational study in Instrumental Delivery; Nec, Affecting Fetus or Newborn, sponsored by Poitiers University Hospital. Completed at 1 site in France. Open to participants aged 12 Hours to 72 Hours. Per ClinicalTrials.gov, last updated 2019-01-29.

Sponsored by Poitiers University Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
12 Hours to 72 Hours
Sex
All
01

Study summary

The aim of this study is to compare the impact of instrumental delivery on newborn head mark and newborn comfort over the impact of non-instrumental delivery. It is also to evaluate how mothers age, Body Mass Index, instrumental extraction indication, extractor type, variety and height of the fetal presentation, operator, time of birth (day or night) and birth weight impact on head mark existence and newborn comfort.

02

Conditions studied

  • Instrumental Delivery; Nec, Affecting Fetus or Newborn
03

In context

Enterocolitis, Necrotizing

228 studies on the registry are indexed under Enterocolitis, Necrotizing; 44 are open to participants now.

This study's enrollment of 300 is above the median of 144 across 95 observational studies indexed under Enterocolitis, Necrotizing.

Browse Enterocolitis, Necrotizing studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Hours to 72 Hours
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

mature newborns who profit an instrumental delivery or not.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • term infant
  • non-opposition of the newborn parent

Exclusion criteria

Exclusion Criteria:

  • outborn child
  • premature newborn
  • newborn transferred
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • Cases

    newborns who were delivered with an extractor

    Other: instrumental delivery

  • Controls

    newborns who were not delivered with an extractor

Interventions

  • Otherinstrumental delivery

    the birth was assisted with an extractor.

06

What researchers measure

Primary outcomes

  1. Head mark or injury

    Any mark or injury (skin erosion, wound, hematoma, fracture, paralysis, etc.) on the newborn head will be described (type, color, size, position) and documented (photo)

    Time frame: 12 to 72 hours of age

  2. Newborn comfort

    assessed using Newborn Pain and Discomfort Scale (EDIN) (DEBILLON et al. Development and initial validation of the EDIN scale, a new tool for assessing prolonged pain in preterm infants. Arch Dis Child Neonatal Ed 2001;85:36-41)

    Time frame: 12 to 72 hours of age

Secondary outcomes

  1. Analgesic use

    Any analgesic administration to the newborn will be reported

    Time frame: 0 to 72 hours of age

  2. Length of hospitalisation after childbirth

    The day out for home of the newborn will be reported

    Time frame: First month of life

07

Study locations

1 site
  • Poitiers University Hospital
    Poitiers, 86000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Oct 2018, 10 months.

Of 39 observational studies under Enterocolitis, Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 115. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 9, 2017
StartActual
Dec 4, 2017
Primary completionActual
Oct 4, 2018
CompletionActual
Oct 4, 2018
Last update
Jan 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03337880
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
Dec 4, 2017
Primary completion
Oct 4, 2018
Completion
Oct 4, 2018
Last update
Jan 29, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion